Predict your next investment

Venture Capital
FINANCE | Investment Firms & Funds
lumiraventures.com

See what CB Insights has to offer

Investments

155

Portfolio Exits

39

Funds

3

About Lumira Ventures

Lumira Ventures collaborates with and invests in entrepreneurial management teams to build best-in-class, innovation-centric biotherapeutic and medical device companies that are meeting significant unmet needs and creating transformation impact in communities worldwide. Since 1989, Lumira Ventures has invested in over 100 healthcare companies and currently has a portfolio of 30+ active investee companies located in Canada and the United States.

Lumira Ventures Headquarter Location

141 Adelaide St. W. Ste. 770

Ontario, M5H 3L5,

Canada

416-213-4223

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Lumira Ventures Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Lumira Ventures Rank

Latest Lumira Ventures News

Corvia Medical Closes USD 54M Funding

Jun 13, 2022

Corvia Medical, a Tewksbury, MA-based company dedicated to transforming the treatment of heart failure (HF), raised USD 54M in funding. Backers included Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, and Edwards Lifesciences.

Lumira Ventures Investments

155 Investments

Lumira Ventures has made 155 investments. Their latest investment was in Congruence Therapeutics as part of their Series A on February 2, 2022.

CBI Logo

Lumira Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/8/2022

Series A

Congruence Therapeutics

$50M

Yes

7

12/16/2021

Seed VC

Specific Biologics

Yes

1

12/8/2021

Series B

OncoMyx

$50M

Yes

17

11/16/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/3/2021

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/8/2022

12/16/2021

12/8/2021

11/16/2021

11/3/2021

Round

Series A

Seed VC

Series B

Series A

Series B - II

Company

Congruence Therapeutics

Specific Biologics

OncoMyx

Subscribe to see more

Subscribe to see more

Amount

$50M

$50M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

7

1

17

10

10

Lumira Ventures Portfolio Exits

39 Portfolio Exits

Lumira Ventures has 39 portfolio exits. Their latest portfolio exit was Bardy Diagnostics on August 06, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/6/2021

Acquired

$99M

15

6/5/2020

Acquired

$99M

6

9/13/2019

IPO

$99M

Public

3

6/7/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/7/2019

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/6/2021

6/5/2020

9/13/2019

6/7/2019

6/7/2019

Exit

Acquired

Acquired

IPO

Acquired

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

15

6

3

10

10

Lumira Ventures Fund History

3 Fund Histories

Lumira Ventures has 3 funds, including Lumira Capital IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/26/2021

Lumira Capital IV

$220M

5

Lumira Capital II

$99M

10

Merck-Lumira Biosciences Fund

$99M

10

Closing Date

7/26/2021

Fund

Lumira Capital IV

Lumira Capital II

Merck-Lumira Biosciences Fund

Fund Type

Status

Amount

$220M

$99M

$99M

Sources

5

10

10

Lumira Ventures Team

6 Team Members

Lumira Ventures has 6 team members, including current Chief Financial Officer, Jacki Jenuth.

Name

Work History

Title

Status

Jacki Jenuth

Chief Financial Officer

Current

Vasco Larcina

Chief Financial Officer

Current

Peter van der Velden

Canadian Venture Capital and Private Equity Association, MDS Capital, Fusion Capital, Taurus Capital, and Bedford Capital

Managing General Partner

Current

Gerry Brunk

MDS Capital, ActiveCyte, The Boston Consulting Group, Credit Suisse First Boston, MAKO Surgical, and Vivre

Managing Director

Current

Daniel Hetu

Managing Director

Current

Name

Jacki Jenuth

Vasco Larcina

Peter van der Velden

Gerry Brunk

Daniel Hetu

Work History

Canadian Venture Capital and Private Equity Association, MDS Capital, Fusion Capital, Taurus Capital, and Bedford Capital

MDS Capital, ActiveCyte, The Boston Consulting Group, Credit Suisse First Boston, MAKO Surgical, and Vivre

Title

Chief Financial Officer

Chief Financial Officer

Managing General Partner

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.